Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer

Toxicity and response criteria of the Eastern Cooperative Oncology Group

Martin M. Oken, Richard H. Creech, Douglass C. Tormey et al. · American Journal of Clinical Oncology · 1982 · 11.6K citations

Pharmacy, Oncology, Medical Oncology +8

Nonparametric Estimation from Incomplete Observations

Edward L. Kaplan, Paul Meier · Journal of the American Statistical Association · 1958 · 7.8K citations

Public Health, Biostatistics, Mathematics +10

Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer

William P. McGuire, William J. Hoskins, Mark F. Brady et al. · New England Journal of Medicine · 1996 · 2.9K citations · Full text

Medicine, Gynecology, Oncology +16

2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines

Howard Ozer, Jamés O. Armitage, Charles L. Bennett et al. · Journal of Clinical Oncology · 2000 · 1K citations

Medicine, Hematology, Oncology +8

Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11.

Yasuyoshi Kawato, Masashi Aonuma, Yasuhide Hirota et al. · PubMed · 1991 · 874 citations

Medicine, Oncology, Pharmacology +13